Signals Inbox·August 25, 2026·Consumer Health

Why does Oura need an IPO now?

Oura does not need an IPO to survive. It needs the public market now because shareholder liquidity, acquisition currency, healthcare expansion and an unusually strong growth story have all become more valuable at the same time.

Q1What is Oura actually trying to do with this IPO?

Oura is currently trying to raise up to $3 billion in a U.S. IPO that could value the smart-ring company above $16 billion, while also giving existing shareholders a chance to sell a meaningful amount of stock.

Bloomberg now reports that Oura and some of its backers are considering an offering as soon as the coming weeks. The terms can still change, but the size is striking. At the upper end, $3 billion of gross proceeds would equal almost 19% of a $16 billion headline valuation.

The timing also comes after a very fast repricing of the company. Oura was valued at $5.2 billion after its Series D in late 2024. Its next large financing, led by Fidelity, valued the company at about $11 billion after Oura announced more than $900 million of new funding. The proposed IPO could push that value beyond $16 billion.

Oura had already confidentially submitted its IPO paperwork to the SEC in May 2026, so the latest reporting is more than another vague “considering an IPO” story. The company has been preparing for a listing, bankers are working on it, and Bloomberg says Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co. and Jefferies are involved.

The big question is therefore why Oura wants to cross into the public market now, when private investors have clearly been willing to keep funding it.

Oura funding and valuation trajectory

Q2Does Oura actually need the IPO cash?

No. Oura currently looks more like a company choosing to go public from a position of financial strength than one being forced into an IPO because it needs cash.

Oura announced more than $900 million of fresh funding in 2025. Around the same period, it secured a separate $250 million revolving credit facility from JPMorgan Chase, Goldman Sachs, Bank of America, Barclays, Citi and Wells Fargo. The company said that facility would support working capital and growth.

There is also no obvious profitability crisis driving the decision. When Oura disclosed more than $500 million of 2024 revenue and its plan to exceed $1 billion the following year, it said profitability was continuing to improve.

More recently, Eli Lilly made an undisclosed equity investment in Oura after the companies began working together through LillyDirect. Oura said the new capital would help it develop connected-care tools, particularly as it builds products around metabolic health and GLP-1 use. More than 100,000 Oura members had already logged GLP-1 use in the app when the investment was announced.

Put those pieces together and Oura still has several ways to finance growth without listing its shares. Private investors, strategic investors and major banks have all supplied capital lately. The IPO solves a broader set of problems than simply putting money in the bank.

Q3If Oura has enough cash, who really needs the IPO?

Oura's existing shareholders probably have at least as much reason to want the IPO as Oura itself does.

That becomes much clearer in the latest Bloomberg reporting. Existing investors are expected to sell a significant amount of stock in the offering. We still do not know how the final deal will be split between newly issued shares and shares sold by current holders, but the presence of a substantial secondary component changes how we should read the IPO.

Oura was founded in 2013 and has gone through many funding rounds. Its investor base includes Fidelity, ICONIQ, Temasek, Coatue, Forerunner Ventures, The Chernin Group, Dexcom and other funds that entered at very different points in the company's life.

Private-company shares can be sold through secondary transactions, and Oura has had some secondary activity before. A public listing creates a much deeper market. After lockups and other restrictions expire, employees and investors can gradually turn shares into cash without waiting for another negotiated financing.

The potential gains are also large enough to make that attractive. Oura's private valuation rose from roughly $2.6 billion in 2022 to $5.2 billion in 2024 and about $11 billion in 2025. An IPO would finally put a continuously traded price on years of accumulated paper gains.

Shareholder liquidity looks like a central part of the timing, especially now that Oura is large enough to support a meaningful public float.

Q4Is Oura going public while its growth still looks exceptional?

Yes. Oura's current growth numbers are unusually strong for a consumer-hardware company approaching public-market scale, and this may be the cleanest growth story the company will ever be able to show investors.

Oura generated more than $500 million of revenue in 2024, more than twice the previous year's level, and said it was on track to exceed $1 billion in 2025. The company later told investors that it expected more than $1.5 billion in 2026 sales.

Another company disclosure gives us a wider view. Oura said in May 2026 that total revenue had grown more than fourfold over the previous two fiscal years. Paid membership had also increased more than fourfold in two years, taking Oura to roughly five million paying members.

Those customers appear unusually engaged. Oura says more than 80% of members renew after their first year, while 80% open the app at least five days a week. Retail distribution has expanded to more than 4,600 locations globally.

The hardware trajectory had already shown the same acceleration. Oura reported 5.5 million cumulative rings sold in 2025, with more than half of those sales coming during roughly the previous year. In other words, Oura sold more rings in about one year than it had during most of its earlier commercial history combined.

That is the kind of curve companies generally want to take public before percentage growth naturally starts coming down.

Oura growth and engagement indicators

Q5Can Oura really justify a $16 billion IPO valuation?

Oura can make a serious case for a valuation above $16 billion today, although public investors will have to believe the company deserves to trade more like a health platform than a normal electronics manufacturer.

The useful comparison is with forward revenue. Oura reportedly expects sales above $1.5 billion in 2026. A $16 billion valuation would therefore equal about 10.7 times that revenue, and anything above $16 billion pushes the multiple higher.

That is expensive for hardware. Oura's argument becomes more interesting once we look at what sits behind the ring sale.

The company now has around five million paid members. More than 80% renew after the first year, and the app remains part of the daily routine for a large majority of them. That gives Oura recurring revenue attached to a device business instead of forcing it to start from zero every time someone finishes buying a ring.

The comparison with Whoop is also useful. The Financial Times reported earlier this year that Whoop had reached an $800 million annual revenue run rate, 2.5 million users and a valuation above $10 billion. Investors are clearly willing these days to put large software-like valuations on health wearables when recurring engagement is strong.

The risk for Oura is that public markets will soon see the exact numbers. Hardware gross margin, subscription margin, marketing costs, churn, inventory and cash flow will all become much harder to blur together once its financial statements are public.

Wearable-health valuation references

Q6Is Oura becoming a subscription business or is it still mostly selling rings?

Oura currently has the customer behavior of a subscription company, even though the ring itself still plays a huge role in how the business makes money.

Five million paid members is already a very large subscription base. The more interesting number is the retention: Oura says more than 80% of members renew after the first year. Its current enterprise material also says roughly 80% of members open the Oura app at least five days each week.

That gives Oura something most consumer-device companies would love to have. Selling the hardware creates the customer relationship, then the software keeps generating revenue and usage after the initial purchase.

We should still be careful about calling Oura a software company. The confidential filing means public investors have not yet seen the detailed revenue mix, gross margins or cohort economics that would let us judge exactly how valuable those subscriptions are.

The IPO will force that question into the open. If recurring revenue is growing faster than ring sales, retention remains high and software margins are strong, Oura can support a much richer valuation. If most of the economics still depend on continually selling expensive new hardware, the comparison with high-margin subscription businesses becomes harder.

For now, the membership numbers are strong enough that investors cannot treat the subscription as a cosmetic add-on.

Q7Is Oura still really a smart-ring company?

Less and less. Oura is currently using the ring as the entry point into a much broader preventive-health product.

The clearest recent example is Oura Ring 5. The new device is 40% smaller than its predecessor, but the bigger change sits in the software around it. Oura launched Health Radar to watch for unusual cardiovascular and respiratory patterns, added GLP-1 insights, expanded health-record integration and pushed further toward predictive rather than purely retrospective health tracking.

The company also says it now works with more than 1,200 organizations across healthcare, wellness and commercial partnerships. Those relationships range from U.S. Soccer and Olympic teams to health plans, fertility providers, employers and clinical organizations.

Then there is the data Oura already has. The company says 57% of its U.S. members report at least one chronic condition. More than 26 million menstrual cycles and more than 350,000 pregnancies have been logged in Oura. Those datasets are far removed from the original pitch of measuring sleep and readiness for quantified-self enthusiasts.

Oura still needs people to buy and wear a ring, of course. But the company increasingly wants the valuable part of the relationship to be what happens after the ring starts collecting data.

That broader story is much easier to sell to public investors than “we dominate smart rings,” because a $16 billion-plus company ultimately needs a market much bigger than one wearable form factor.

Q8Is Oura's push into healthcare making the company more expensive to build?

Yes. Oura is moving into areas where clinical expertise, AI infrastructure, privacy, security and medical integrations all cost substantially more than adding another fitness feature to an app.

We can see the change in what Oura has been building lately. The company has developed its own women's-health AI model using clinician-curated knowledge. It has started bringing electronic health records into the Oura app. Its blood-pressure work includes an IRB-approved study designed to identify hidden hypertension risk. Oura has also obtained SOC 2 and HITRUST accreditations around sensitive health data.

The talent mix is changing too. Oura said in 2025 that it employed more than 30 doctors and PhDs. More recently, it reorganized its technology leadership, bringing in a new chief information officer and putting a senior executive specifically in charge of AI and software engineering. The Wall Street Journal reported that Oura wants to build more proprietary health-specific AI rather than rely only on general-purpose models.

Oura also acquired Galen AI this year. Galen was building a personal health assistant capable of bringing together medical records, lab results, medications and wearable data. Oura took the technology and the team, giving us a fairly clear picture of where its product ambitions are heading.

All of that can create a much bigger company. It also raises the amount Oura needs to spend on people, research, infrastructure, security and regulatory work while it gets there.

Q9Does Oura need public stock to keep buying health-tech companies?

Probably. Acquisitions are becoming a recurring part of Oura's expansion, and a liquid public share price would make larger deals much easier.

Oura has now bought or absorbed technology from Proxy, Veri, Sparta Science, Doublepoint and Galen AI. The pattern is more interesting than the number of deals.

Veri brought metabolic-health expertise. Sparta Science added enterprise health and performance analytics. Doublepoint brought gesture control, biometrics and human-computer interaction. Galen AI brought software that combines clinical records, labs, medication information and wearable data.

That is a surprisingly broad shopping list for a company that was once mainly known for sleep tracking. We can see Oura filling gaps in the platform by acquiring small specialist teams instead of building every capability from scratch.

Proxy also showed that Oura is comfortable using shares as acquisition currency: the 2023 transaction was an all-equity deal.

Public shares make that mechanism more useful. A startup selling itself to Oura can more easily value liquid stock than private shares whose price changes only during occasional funding rounds. Larger acquisitions also become easier to finance with a mix of stock, cash and debt.

If Oura keeps moving into AI, metabolic health, women's health and clinical data, its acquisition pipeline could become much more important than it has been historically.

Q10Is competition forcing Oura to IPO now?

Competition is giving Oura a reason to move faster, even though Oura still looks like the company to beat in smart rings today.

Samsung changed the category when it launched Galaxy Ring. Samsung has vastly more distribution, manufacturing scale and existing device users than Oura. Apple has yet to launch a ring, but Bloomberg reports that it continues exploring new AI-powered wearable formats. Oura therefore cannot assume the ring category will remain its private territory.

Whoop creates pressure from another direction. It competes for many of the same health-conscious customers without using a ring at all, and its recent $10 billion-plus valuation shows that investors increasingly see screenless health wearables as a meaningful category rather than a niche gadget business.

Oura has defended its position aggressively. The U.S. International Trade Commission ruled in its favor in its patent dispute involving Ultrahuman and RingConn, giving Oura real legal leverage over smaller ring competitors. RingConn subsequently moved toward licensing Oura's intellectual property.

That protects part of the hardware advantage. It does much less against a company that changes the form factor or builds a stronger software ecosystem.

Oura's best current defense is speed: build the largest membership base, accumulate the deepest longitudinal health data, add healthcare integrations and turn the ring into one part of a harder-to-copy platform. An IPO can give the company more resources and a more useful currency while that lead still exists.

Q11Has Oura been quietly preparing to become a public company?

Yes. Oura has spent the past several months making changes that fit unusually well with a company getting ready for public markets.

One of the clearest moves came in February 2026, when Oura started shifting its legal parent company from Finland to the United States. CEO Tom Hale explained that most of the company's revenue and investors were already in the U.S. and that the new structure would make the business simpler to run.

Three months later, Oura announced its confidential IPO submission.

Governance had already started changing. When the large Series E was announced, longtime director David Shuman became board chair and the company expanded its board. Oura has since kept strengthening the management layer underneath Hale, particularly around AI, software and data infrastructure.

The company's center of gravity has moved as well. Oura still has major Finnish operations, but it describes San Francisco as its headquarters and the U.S. as its biggest commercial and investor market.

Any one of those moves could have happened without an IPO. Seen together, the sequence is pretty straightforward: simplify the corporate structure, strengthen governance, upgrade technology leadership, prepare the SEC paperwork and then begin talking to public investors.

Oura has been getting ready for this for a while.

Q12Is the IPO market good enough for Oura to go public now?

Yes. The U.S. IPO market is currently much more welcoming than it was during the long slowdown that followed the 2021 boom, particularly for large companies that can show real revenue and growth.

PwC counted 65 traditional U.S. IPOs raising about $114 billion in the first half of 2026, compared with only $14.8 billion during the same period a year earlier. Even after accounting for the extraordinary impact of very large listings, activity has picked up sharply.

EY reached a similar conclusion. It found that the number of U.S. offerings raising more than $50 million increased from 34 to 62 year over year, while companies in that group had risen nearly 20% on average by the end of the first half.

The market has remained active lately. The Wall Street Journal reports that traditional U.S. IPOs have now raised about $137 billion and that companies including Oura are actively meeting fund managers ahead of another wave of listings.

Public investors are still selective. Several recent technology listings have performed poorly after their initial excitement, and huge AI offerings are competing for attention and capital. That makes valuation discipline important.

Oura nevertheless enters this market with something many IPO candidates lack: billion-dollar-scale revenue, very fast growth, millions of paying customers and improving profitability. Waiting for an even better IPO environment would be a gamble.

Q13Could Oura hurt itself by waiting another year or two?

Yes. Oura could become a better business while simultaneously becoming a less exciting IPO.

Growth is the obvious reason. Doubling a $500 million business is possible, and Oura has essentially done it. Doubling a $1.5 billion business requires another $1.5 billion of annual sales. Eventually the percentages have to come down, even if the company keeps adding hundreds of millions of dollars of revenue each year.

The competitive story could also become messier. Samsung already has a ring. Whoop is expanding deeper into health. Larger technology companies have the resources to build new wearables, health AI and sensor products. Oura's current position as the clear company most associated with smart rings is valuable precisely because the category has not fully matured yet.

Then there is the market itself. IPO windows have opened and closed quickly over the past few years. Oura currently has strong growth numbers at the same time that investors are again putting serious money into new listings. There is no guarantee those conditions will line up again when Oura is ready.

Waiting could still pay off if Oura's revenue keeps compounding, healthcare products take off and margins improve sharply. But the company would be trading today's known combination of growth and market appetite for an unknown one later.

These days, Oura has a story that is easy to understand: category leader, roughly five million paid members, a fast-growing preventive-health platform and a business moving beyond a single device. That simplicity itself has value during an IPO.

Q14So why does Oura need an IPO now?

Oura does not appear to need an IPO for survival or basic financing. The stronger explanation is that going public has become more useful to Oura now than staying private.

The latest proposed deal can do several things at once. Existing shareholders get a serious liquidity route. Oura can raise far more capital than it needs for ordinary working capital. Public stock gives the company a better currency for acquisitions. A traded valuation makes employee equity easier to value. And Oura gains access to public markets just as its ambitions are expanding from smart rings into AI, preventive health and connected care.

Timing is doing a lot of the work. Oura currently has the growth profile companies normally dream of taking public. Its customer base is measured in millions, retention is high, its newest product pushes further into predictive health, and recent moves such as the Galen AI acquisition and Eli Lilly investment give the broader healthcare story more substance than it had even a year ago.

Meanwhile, public investors are buying IPOs again.

So the word “need” deserves a narrow interpretation here. Oura could remain private. It has plenty of evidence that investors and banks would keep funding it. What Oura may struggle to recreate later is this exact combination of rapid growth, clear category leadership, eager shareholders, an expanding health-platform story and an open IPO market.

That makes the IPO look timely rather than necessary. Oura has reached one of those rare moments when cashing in on its momentum may be more valuable than waiting to become an even bigger private company.